Clinical Research Directory

Inclusion Criteria: * Age between 18 and 80 years (gender is not restricted). * STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the "Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019" and the fourth - edition "Global Definition of Myocardial Infarction" criteria, myocardial infarction refers to acute myocardial injury \[serum cardiac troponin (cTn) increases and/or decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.) * Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \< 20% after stent implantation or \< 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2). * Signed a written informed consent form. Exclusion Criteria: * Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia. * LVEF \< 40%. * Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc. * Unable to undergo CMR examination for various reasons. * Expected to be unable to complete 6 - month treatment with Guanxinning Tablets. * Contraindications or allergies to Guanxinning Tablets. * Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.). * Active or chronic liver disease. * Renal insufficiency (eGFR \< 60ml/min/1.73m²). * History of previous cerebral hemorrhage. * History of alcohol or drug abuse. * Known active infection, or severe hematological, metabolic, or endocrine dysfunction. * Patients who have received systemic steroid or cyclosporine treatment in the past 3 months. * Active malignant tumor. * Life expectancy less than 6 months. * Pregnant or lactating women. * Already participating in other clinical studies.